1. Home
  2. BSVN vs ALT Comparison

BSVN vs ALT Comparison

Compare BSVN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank7 Corp.

BSVN

Bank7 Corp.

HOLD

Current Price

$39.95

Market Cap

384.9M

Sector

Finance

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.43

Market Cap

415.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSVN
ALT
Founded
2004
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
384.9M
415.3M
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
BSVN
ALT
Price
$39.95
$3.43
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$53.33
$17.67
AVG Volume (30 Days)
4.9K
2.8M
Earning Date
04-15-2026
06-10-2026
Dividend Yield
2.74%
N/A
EPS Growth
N/A
25.37
EPS
4.50
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$4.59
N/A
Revenue Next Year
$7.19
$756,308.50
P/E Ratio
$8.87
N/A
Revenue Growth
N/A
105.00
52 Week Low
$32.49
$2.91
52 Week High
$50.10
$7.73

Technical Indicators

Market Signals
Indicator
BSVN
ALT
Relative Strength Index (RSI) 33.05 33.97
Support Level $37.56 $3.40
Resistance Level $43.22 $4.25
Average True Range (ATR) 1.06 0.23
MACD -0.15 -0.04
Stochastic Oscillator 0.00 3.77

Price Performance

Historical Comparison
BSVN
ALT

About BSVN Bank7 Corp.

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: